Publications by authors named "Michalis Kodounis"
Chronic migraine (CM) imposes significant personal, societal, and financial burdens, historically lacking specific prophylactic treatments. Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) represent a novel, mechanism-based, and migraine-specific prophylactic approach. Four mAbs, namely, erenumab, fremanezumab, galcanezumab, and eptinezumab, have been marketed, although head-to-head trials with standard anti-migraine treatments are absent.
View Article and Find Full Text PDFArticle Synopsis
- Migraine is a complex neurovascular disorder influenced by inflammatory mediators and sex steroid hormone fluctuations, which contribute to the differing impacts on men and women.
- The hormones prolactin and oxytocin play significant roles in the pathophysiology of migraines; prolactin has a pronociceptive (pain-enhancing) effect while oxytocin exhibits an antinociceptive (pain-reducing) effect.
- Effective migraine treatments may involve targeting these hormones: blocking prolactin's effects using receptor antagonists and enhancing oxytocin's effects through methods like intranasal administration, while also recognizing the unique interactions with estrogen and other pain-related pathways.
Background-purpose: It is critical that Randomized Controlled Trials(RCTs) present complete and transparent reporting. The present study aims to determine the reporting quality of double-blind RCTs for medicinal interventions in patients with ischemic stroke, based on the 2010 CONSORT-statement.
Methodology: MEDLINE was comprehensively searched.